scout
|Videos|November 16, 2017

Dr. Epperla on FDA Approval of Frontline Obinutuzumab in Follicular Lymphoma

Narendranath Epperla, MBBS, MS, hematologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of frontline obinutuzumab (Gazyva) for the treatment of patients with follicular lymphoma.

Narendranath Epperla, MBBS, MS, hematologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of frontline obinutuzumab (Gazyva) for the treatment of patients with follicular lymphoma.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME